ReviewInternational journal of colorectal disease2010
Serum interleukin-6 levels in colorectal cancer patients--a summary of published results.
Review in International journal of colorectal disease, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 149 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
149 citing papers in PubMed, 4 syntheses or guidelines pooled it, 298 citations in OpenAlex.
- Predictive value of serum cytokines in patients with non-small-cell lung cancer receiving anti-PD-1 blockade therapy: a meta-analysis.Clinical and experimental medicine · 2025Pooled it
- Effects of omega-3 fatty acids on patients undergoing surgery for gastrointestinal malignancy: a systematic review and meta-analysis.BMC cancer · 2017Pooled it
- Pooled it
- Pooled it
- Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.Investigational new drugs · 2014Trial
- Seroprevalence of Toxoplasma gondii infection, associated risk factors, and circulating IL-6 and VEGF-A levels in colorectal cancer patients: a case-control study from western Iran.BMC infectious diseases · 2026Article
- In Vitro Antitumor Properties of Simvastatin-Loaded SBA-16 Mesoporous Nanoparticles Using Two- and Three-Dimensional Colorectal Spheroid Models.Pharmaceutics · 2026Article
- Article
- Article
- Article
- MCPIP1 Controls Hybrid EMT and Tumor Stemness via the IL6/JAK2/STAT3 Axis in Pancreatic Cancer.Cancer medicine · 2025Article
- Design, synthesis and bioactivity evaluation of phosphinanes as potential anticancer agents.Scientific reports · 2025Article
- The Anti-Inflammatory, Immunomodulatory, and Pro-Autophagy Activities of Probiotics for Colorectal Cancer Prevention and Treatment: A Narrative Review.Biomedicines · 2025Review
- Oxidative Stress and Inflammation: Drivers of Tumorigenesis and Therapeutic Opportunities.Antioxidants (Basel, Switzerland) · 2025Review
- Circulating IL6 is involved in the infiltration of M2 macrophages and CD8+ T cells.Scientific reports · 2025Article
- Article
- Berberine inhibits colorectal liver metastasis via modulation of TGF-β in a cecum transplant mouse model.European journal of medical research · 2024Article
- Targeting CREB-binding protein (CBP) abrogates colorectal cancer stemness through epigenetic regulation of C-MYC.Cancer gene therapy · 2024Article
- Systemic Immunological Changes After Yttrium-90 Radioembolization: A Pilot Prospective Observational Study-Clinical Insights.Cardiovascular and interventional radiology · 2024Observational
- EPA, DHA, and resolvin effects on cancer risk: The underexplored mechanisms.Prostaglandins & other lipid mediators · 2024Review
89 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIt is now clear that inflammation and cancer initiation and progression are linked. Interleukin-6 (IL-6) is a pleiotropic inflammatory cytokine with described cancer stimulatory and also cancer inhibitory properties. The study's aim was to assess the potential of circulating IL-6 as a prognostic indicator in colorectal cancer. MATERIALS AND
methodsA literature search was conducted using PubMed, restricted to articles published in English language. We compared published results in regard to differences in IL-6 levels between healthy controls and colon cancer patients (seven published results), between patients with increasing tumor stages (eight published results), between patients with differences in tumor size (four published results), and between patients with and without liver (three published results) or lung metastasis (one published result). Furthermore, we reviewed the literature in regard to the possible correlation of IL-6 levels with survival time (five published results) and correlation of IL-6 levels and lymph node involvement (three published results).
resultsConcerning colon tumors, results are consistent. Colon cancer patients reveal higher serum IL-6 levels than healthy controls. Furthermore, higher IL-6 levels are associated with increasing tumor stages and tumor size, with metastasis and decreased survival.
conclusionTherefore, circulating IL-6 might be prognostic indicator in colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.